Sanofi S.A., FR0000120578

Sanofi stock after-hours at EUR 70.63: minus 2.61 percent versus prior close

Published on 10/02/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock is at EUR 70.63 after-hours at 7:20 p.m. CEST, down 2.61 percent versus the Lang & Schwarz prior close. Sanofi and Regeneron expanded their antibody alliance.

Overhead flatlay of pharmaceutical objects on white surface including clear glass vials, a syringe, petri dish, test tubes, a pipette, and blue nitrile gloves
Sanofi FR0000120578 overhead flatlay of pharmaceutical vials, syringe, pipette, petri dish, and protective gloves, Illustration mit AI erstellt.

Sanofi stock is at EUR 70.63 after-hours, down 2.61 percent versus the prior close of EUR 72.52 at Lang & Schwarz. The price was recorded on October 2, 2026, at 7:20 p.m. CEST.

Sanofi stock during after-hours trading

The Lang & Schwarz quote was EUR 70.63, compared with a prior close of EUR 72.52. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Sanofi stock.

Sanofi and Regeneron expand antibody alliance

On October 1, 2026, Sanofi and Regeneron announced an expansion of their longstanding antibody collaboration. The agreement adds four new long-acting, Regeneron-invented antibodies targeting interleukin-13, an IL-4xIL-13 bispecific, interleukin-4 and interleukin-4 receptor alpha.

Under the agreement, Regeneron will receive USD 1 billion upfront and may receive up to an additional USD 7 billion in development, regulatory and commercial milestone payments. The companies will share development and commercialization costs and split future profits from the potential products equally worldwide. Regeneron will lead research and development, while Sanofi will lead global commercial efforts. The existing profit-sharing agreement for Dupixent will not change.

Disclaimer...

en | FR0000120578 | SANOFI S.A. | boerse | 70217308 | bgmi